The human diseases caused by the fungal pathogens Cryptococcus neoformans and C. 24 gattii are associated with high indices of mortality, and toxic and/or cost-prohibitive 25 therapeutic protocols. The need for affordable antifungals to combat cryptococcal 26 disease is unquestionable. Previous studies suggested benzimidazoles as promising 27 anti-cryptococcal agents combining low cost and high antifungal efficacy, but their 28 therapeutic potential has not been demonstrated so far. In this study, we investigated 29 the antifungal potential of fenbendazole, the most effective anti-cryptococcal 30 benzimidazole. Fenbendazole was inhibitory against 30 different isolates of C. 31 neoformans and C. gattii at a low concentration. The mechanism of anti-cryptococcal 32 activity of fenbendazole involved microtubule disorganization, as previously described 33 for human parasites. In combination with fenbendazole, the concentrations of the 34 standard antifungal amphotericin B required to control cryptococcal growth were 35 lower than those required when this antifungal was used alone. Fenbendazole was not 36 toxic to mammalian cells. During macrophage infection, the anti-cryptococcal effects 37 of fenbendazole included inhibition of intracellular proliferation rates and reduced 38 phagocytic escape through vomocytosis. Fenbendazole deeply affected the 39 cryptococcal capsule. In a mice model of cryptococcosis, the efficacy of fenbendazole 40 to control animal mortality was similar to that observed for amphotericin B. These 41 results indicate that fenbendazole is a promising candidate for the future development 42 of an efficient and affordable therapeutic tool to combat cryptococcosis. 43 44 45 200,000 humans each year (1). The disease, which is devastating in sub-Saharan Africa, 48 significantly affects other regions of the globe, including Asia, Oceania, Europe and the 49 Americas (2-4). The World Health Organization (WHO) recommends three therapeutic 50 phases for treating cryptococcal meningitis, including an induction therapy with 51 amphotericin B plus flucytosine (week 1) followed by fluconazole (week 2), a 52 consolidation phase with fluconazole (weeks 3-10) and maintenance therapy of up to 53 12 months also with fluconazole (5). However, amphotericin B and flucytosine are not 54 available in many countries (6). In addition, the effective treatment of human 55 cryptococcosis is cost-prohibitive in most of the regions that are severely affected by C. 56 neoformans and C. gattii. In Malawi, Zambia, Cameroon, and Tanzania, the costs for 57 treating each patient with cryptococcal meningitis includes US $1442 for 2 weeks of 58 oral fluconazole and flucytosine, $1763 for 1 week of amphotericin B and fluconazole, 59 $1861 for 1 week of amphotericin B and flucytosine, $2125 for 2 weeks of 60 amphotericin B and fluconazole, and $2285 for 2 weeks of amphotericin B and 61 flucytosine (7). In Brazil, the therapeutic costs of lipid formulations of amphotericin B 62 can exceed US $100,000 per patient (8). In summary, novel therapeutic protocols for 63 treating the diseases caused by C. neoformans and C. gattii are urgent. However, the 64 development of novel drugs is time-consuming, highly expensive and commonly 65 unsuccessful (9, 10). In this context, drug repurposing has emerged as a promising 66 alternative for the development of novel therapies against neglected pathogens, 67
Introduction 46
Cryptococcosis caused by Cryptococcus neoformans and C. gattii kills almost 47
Flubendazole is inhibitory against all pathogenic Cryptococcus species, including 70 isolates that are resistant to fluconazole (13). In mice, orally administered flubendazole 71 resulted in an expressive reduction in fungal burden in comparison with controls, but 72 in the rabbit model, there were no quantifiable drug concentrations or antifungal 73 activity in the cerebrospinal fluid or brain (15) . Mebendazole, another member of the 74 family of benzimidazoles, also showed antifungal activity against C. neoformans, 75
including phagocytized yeast cells and cryptococcal biofilms (16) . 76
The anti-cryptococcal effects of other benzimidazoles have been superficially 77 examined. In comparison to other benzimidazoles, fenbendazole was the most 78 efficient compound showing in vitro fungicidal activity (16), but mechanistic 79 approaches and in vivo activity of this compound were not evaluated. Fenbendazole 80 has been licensed worldwide for the treatment and control of helminth infections in 81 food and non-food producing animals for more than 30 years and its safety is well 82 established. According to the European Medicines Agency (17), fenbendazole had 83 negligible acute toxicity in single-dose animal studies and no points of concern relevant 84 for the safety of fenbendazole in humans could be identified. No treatment-related 85 effects were observed in the offspring of dogs, pigs, sheep, and cattle administered 86 fenbendazole at various times during gestation. Finally, the compound was not 87 genotoxic, and no evidence for carcinogenicity was found (17, 18) . 88
Based on the anti-cryptococcal effects of fenbendazole (16) and negligible 89 toxicity to humans and animals (17, 18) , we evaluated the therapeutic potential of this 90 benzimidazole against pathogenic cryptococci. Our results demonstrated that 91 fenbendazole was inhibitory against several strains of C. neoformans and C. gattii. The 92 mechanism of antifungal activity of fenbendazole involved the functionality of 93 microtubules. Fenbendazole had low toxicity to mammalian cells alone or in 94 combination with amphotericin B and its antifungal effects included inhibition of 95 virulence determinants and reduced proliferation of Cryptococcus inside macrophages. 96
Finally, fenbendazole was highly effective in a mice model of cryptococcosis. These 97 results support the use of fenbendazole as a prototype for the development of novel 98 pharmaceutical preparations for treating cryptococcosis. 99 100 101 (FICI) corresponded to 0.62 for the H99 strain and 0.49 for the R265 isolate, suggesting 126 that fenbendazole was slightly more synergistic with amphotericin B against C. gattii 127 than C. neoformans. 128 129 Fenbendazole affects β-tubulin distribution in C. neoformans and C. gattii. We asked 130 whether the mechanism of anti-cryptococcal activity of fenbendazole was similar to 131 what was previously described for C. gattii (16) or if it was related to its well 132 characterized anthelmintic effect (19) (20) (21) . Mutant strains of C. gattii lacking expression 133 of the Aim25 scramblase or the nucleolar protein Nop16 were resistant to 134 mebendazole (16), suggesting that these proteins are potential targets for the 135 antifungal activity of benzimidazoles. To investigate the mechanism of action of 136 fenbendazole, we first evaluated its antifungal activity against mutant strains of C. 137 gattii lacking the AIM25 or NOP16 genes and observed that both strains and wild type 138 cells were similarly sensitive to this benzimidazole (Figures 2A and B ). This result 139 suggested that, in contrast to mebendazole, Aim25 and Nop16 are not required for the 140 antifungal activity of fenbendazole. We then asked whether the inhibitory effect of 141 fenbendazole against C. neoformans and C. gattii involves interference with the 142 functions of β-tubulin, as consistently described for parasites (19, 21) . Staining of β-143 tubulin in fungal cells revealed that fenbendazole-treated fungi and untreated 144 cryptococci had markedly different profiles of microtubule organization. Control cells 145 showed high fluorescence intensity and a well-defined intracellular pattern of β-146 tubulin staining ( Figure 2C ). Fluorescence detection was apparently less intense in 147 drug-treated cells, which also manifested a markedly more disperse staining of β-148 tubulin. In addition, the effects of fenbendazole on -tubulin staining were apparently 149 more drastic in C. gattii than in C. neoformans, as concluded from the weaker signals 150 of β-tubulin staining in the former species. These results indicate that the mechanism 151 antifungal activity of fenbendazole against Cryptococcus is similar to that described for 152 human parasites. 153 154 Intranasal administration of fenbendazole results in the control of animal 155 cryptococcosis. The combination of low toxicity, efficient antifungal efficacy, and 156 defined mechanism of action led us to test the antifungal potential of fenbendazole in 157 vivo. To reduce the number of animals used to a minimum, we selected the standard 158 strain H99 of C. neoformans for the in vivo work, based on the highest prevalence of 159 this species in human disease (3). Metabolization by host tissues is a common feature 160 of orally administered benzimidazoles (22). Fenbendazole, specifically, is rapidly 161 sulfoxidated by liver microsomes after oral absorption (22) . Therefore, we first tested 162 the in vitro antifungal activity of the sulfone-derivative of fenbendazole, which showed 163 no inhibitory potential ( Figure 3A ). We performed similar tests with the liver 164 metabolites of other benzimidazoles (mebendazole, flubendazole and albendazole) 165 and none of them manifested antifungal activity ( Figure 3B -D), suggesting that host 166 metabolization is an important limitation for the antifungal activity of benzimidazoles 167 in general. In fact, orally administered fenbendazole and mebendazole had no effects 168 on mice cryptococcosis (data not shown). Therefore, to avoid liver metabolization and 169 to promote an increased bioavailability of fenbendazole in its native form, we 170 administered the drug intranasally. Under these conditions, mice receiving 171 amphotericin B and fenbendazole had similarly high survival rates, in comparison with 172 vehicle-treated mice (P = 0.0014, Figure 3E ). The experiment was repeated under the 173 same conditions and identical results were obtained. 174 175 Fenbendazole affects the virulence potential of Cryptococcus. We asked whether the 176 high efficacy of fenbendazole in vivo was related to neutralization of virulence 177 determinants in addition to its antifungal effects. Capsule synthesis and intracellular 178 proliferation rates have been consistently associated to the pathogenic potential of 179 cryptococci (23, 24). We therefore evaluated whether fenbendazole was able to 180 interfere with each of these biological events. 181
Microscopic analysis of fenbendazole-treated C. neoformans and C. gattii 182 revealed clear effects on the capsular architecture, although some species-specific 183 particularities were observed. In all cases, fungal aggregates with reduced capsular 184 dimensions were observed after drug treatment ( Figure 4A ). Scanning electron 185 microscopy of the H99 strain of C. neoformans after exposure to fenbendazole 186 revealed shorter and scarcer capsular fibers, in comparison with control cells. This 187 perception was confirmed by immunofluorescence analysis. In C. gattii (strain R265), 188 surface fibers and capsular dimensions were also reduced after exposure to 189 fenbendazole. However, in comparison with drug-treated C. neoformans, 190 fenbendazole was apparently less efficient in reducing the capsular dimensions of C. 191 gattii. In both cases, a dose-dependent reduction of capsular dimensions was observed 192 after cryptococci were treated with fenbendazole ( Figure 4B ). 193
Due to the suggested link between therapeutic failure and intracellular 194 proliferation of cryptococci (23, 25, 26) , we evaluated whether fenbendazole could 195 influence the fate of C. neoformans and C. gattii in infected macrophages. Initial 196 microscopic observation suggested that fenbendazole affected the cell division 197 frequency of both C. neoformans and C. gattii ( Figures 5A and B ). In macrophages 198 infected with C. neoformans that were further treated with DMSO, intracellular 199 division was initially observed 1 h after internalization of fungal cells, with a clear peak 200 at 5 h post phagocytosis ( Figure 5C ). In drug-treated systems, intracellular proliferation 201 was first observed 4 h after phagocytosis, with less intense peaks at 5 and 7 h post 202 infection. In similar systems using C. gattii, intracellular proliferation in vehicle-treated 203 macrophages was first observed 1 h post-infection, with more prominent peaks of 204 replication at 5 and 7 h post-infection ( Figure 5D ). In drug-treated systems, fungal 205 intracellular proliferation was only observed after 5 h. These results were suggestive of 206 lower intracellular proliferation rates (IPR) of phagocytized C. neoformans and C. gattii. 207
Since low IPR have been linked with reduced virulence (23, 25, 27) , we investigated the 208 effects of fenbendazole on this important parameter. 209
In both species, exposure of infected macrophages to fenbendazole resulted in 210 reduced IPR at both inhibitory and sub inhibitory concentrations ( Figures 6A and 6B) . 211
High IPR are related to vomocytosis, a mechanism of phagocytic scape commonly used 212 by Cryptococcus (28, 29). We therefore determined the vomocytosis levels after The in vitro anti-cryptococcal activity of benzimidazoles has been consistently reported 228 (13) (14) (15) (16) . A general analysis of these reports on the anti-cryptococcal activity of 229 benzimidazoles indicated that, among all members of this drug family, fenbendazole 230 required the lowest MIC against C. neoformans and C. gattii, in comparison to other 231 benzimidazoles (13-16). In addition, a detailed study on the toxicity of fenbendazole 232 suggested high levels of safety in humans (17, 18) . In our study, we confirmed the 233 efficacy of fenbendazole as an anti-cryptococcal agent. We tested approximately 30 234 strains of C. neoformans and C. gattii and observed that they were all similarly 235 susceptible to fenbendazole, suggesting that resistance to this benzimidazole might 236 not be an issue in pathogenic cryptococci. A similar MIC of 0.012 g/ml was found for 237 all of them. For comparison, a recent study (15) analyzed 50 strains of C. neoformans 238 according to their susceptibility to flubendazole, another member of the 239 benzimidazole family. Using the same EUCAST methodology, MICs of 0.03 (one strain), 240 0.06 (19 strains), 0.125 (25 strains) and 0.25 (5 strains) g/ml were found in this study. 241
These values were 2.5 to 20-fold higher than the MIC found for fenbendazole in this 242 study. The low toxicity of fenbendazole was also certified in our essay, as well as its 243 ability to improve the antifungal activity of amphotericin B. These characteristics led 244 us to explore the properties of fenbendazole in mechanistic and therapeutic models. 245
In a previous study, we used a mutant collection of C. gattii for determination 246 of the cellular targets of mebendazole, another anti-cryptococcal benzimidazole (16). 247
These mutants were screened for resistance phenotypes in the presence of 248 mebendazole, based on the assumption that, in the absence of a cellular target 249 required for antifungal activity, the drug would lack anti-cryptococcal properties. The 250 mutants showing highest levels of resistance to mebendazole lacked expression of 251 Aim25, a cryptococcal scramblase (30), or Nop16, a putative nucleolar protein (16). We 252 initially assumed that these targets were required for the activity of fenbendazole, but 253 our current results indicate that they are not involved in the antifungal properties of 254 this benzimidazole. In nematodes, the benzimidazoles bind to β-tubulin, leading to 255 local unfolding of the protein and consequent abnormal conformation. This outcome 256 finally results in the inhibition of the polymerization of α-and β-tubulin subunits to 257 form microtubules, causing lethal effects in dividing cells (31). In the C. neoformans 258 model, a similar mechanism was attributed to flubendazole and other benzimidazoles 259 (32). However, fenbendazole was not specifically tested in these studies. In addition, 260 the cellular effects of benzimidazoles on the cryptococcal microtubules were not 261 reported. In our study, treatment of both C. neoformans and C. gattii with 262 fenbendazole led to a clear alteration in β-tubulin detection, strongly suggesting that 263 its mechanism of action is related to that described for the nematodes and other 264 parasites. 265
The benzimidazoles are extensively metabolized in mammals following oral 266 administration. The parent compounds are generally short-lived, and metabolites 267 predominate in plasma, tissues and excreta (22). Fenbendazole, for instance, is rapidly 268 metabolized by liver microsomes after oral absorption. In pigs, this benzimidazole was 269 rapidly absorbed after oral administration, but its systemic bioavailability was low (33). 270
The intranasal route, on the other hand, transport drugs directly to the brain from the 271 nasal cavity along the olfactory and trigeminal nerves (34), avoiding the first-pass 272 metabolism in liver and gastrointestinal tract. These findings agree with our current 273 results showing that all animals infected with C. neoformans and treated with 274 fenbendazole intranasally survived. However, our results also suggest that liver 275 metabolization is a limitation for the oral treatment of fungal diseases with 276 fenbendazole. In this sense, strategies for protecting drug candidates against 277 metabolic modifications are widely available (35) 
Strains and Growth Conditions 305
Cryptococcus neoformans and C. gattii (strains H99 and R265, respectively) were used 306 in most experiments. In addition, 15 isolates of C. neoformans and 12 isolates of C. 307 gattii, obtained from the Collection of Pathogenic Fungi available at Fiocruz, were 308 tested for sensibility to fenbendazole. For studies of mechanism of antifungal activity, 309 the C. gattii mutant strains aim25Δ and nop16Δ were also tested (16, 30) . For the in 310 vitro interaction assays, green fluorescence protein (GFP)-tagged C. neoformans and C. The cells were placed over 0.01% poly-L-lysine-coated coverslips and incubated for 30 414 min at 25 o C. Adhered cells were then gradually dehydrated in ethanol (30, 50, and 70% 415 for 5 min, and then 90% for 10 min, and 100% twice for 10 min). Immediately after 416 dehydration, the cells were critical point dried (Leica EM CPD300), mounted on 417 metallic bases and coated with a gold layer (Leica EM ACE200). The cells were 418 visualized in a scanning electron microscope (JEOL JSM-6010 Plus/LA) operating at 5 419 keV. 420 421 Intracellular antifungal activity 422 RAW 264.7 macrophages were suspended (5x10 5 cells/ml) in DMEM supplemented 423 with 10% FBS, and 200 µl of this suspension was transferred to each well of 96-wells 424 plates for overnight incubation at 37 o C in a 5% CO 2 atmosphere. In the next day, C. 425 neoformans or C. gattii (5 x 10 5 cells/ml) were opsonized by incubation for 1 h at 37 o C 426 under a 5% CO 2 atmosphere in DMEM containing 10% FBS and 5 µg/ml mAb 18B7. Acknowledgements. We are thankful to Drs. Arturo Casadevall for donation of the 472 18B7 antibody and Charley Staats and Ane Garcia for the use of the nop16 and 473 aim25 mutants. We also appreciate the notation of the fluorescent strains by Dr. As preconized by the EUCAST, growth inhibition measurements corresponded to 50% 568 for FLZ and 90% for AmB. FBZ inhibition rates corresponded to 90%. 569 2 Strain numbers were attributed by the Collection of Pathogenic Fungi of Fiocruz. For 570 details, see http://cfp.fiocruz.br/index. 571 3, 4 The C. krusei and C. parapsilosis isolates were used as controls of antifungal activity, 572
as preconized by the EUCAST. The MIC results obtained with these isolates were at the 573 expected range (39). 574 575
